Project Grant R01CA295558
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$608K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic for $458,021.00 to conduct research on maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma. The research aims to:
Evaluate the mechanism of exquisite sensitivity to MDM2 inhibitors in MDM2-amplified glioblastoma.
Define the effects of the MDM2 inhibitor Brigimadlin on cellular response to genotoxic stress.
Evaluate strategies to enhance the...
This $402,401 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is to evaluate the role of the SPAK and OSR1 kinases in mediating chemotherapy resistance in glioblastoma (GBM), the most deadly form of brain cancer. The goal is to determine if inhibiting these stress-sensing kinases, which allow GBM cells to survive hostile environments, can enhance the efficacy of standard chemoradiotherapy. The award, with a project period from Jul 2024 to...
This $639,004 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Mayo Clinic to evaluate the use of a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The award will fund the collection and analysis of tumor tissue and blood samples to investigate the mechanisms by which NT-I7 can enhance immune response and improve the efficacy of checkpoint inhibitor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $404,974 in funding to The Ohio State University to investigate the therapeutic potential of targeting the KIF20A protein in glioblastoma, an aggressive brain cancer. The research aims to characterize the role of KIF20A in early mitosis and evaluate the impact of a KIF20A inhibitor as a single agent and in combination with radiation therapy in glioblastoma patient-derived models. The...
The National Cancer Institute (NCI) awarded a $472,447 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Mayo Clinic for a 5-year project to evaluate the preclinical and clinical activity of DNA methyltransferase (DNMT) inhibitors in combination with chemoimmunotherapy for triple-negative breast cancer (TNBC). The project aims to identify predictive biomarkers, such as DNMT3A expression, and elucidate the mechanisms of action of this combination therapy, including the role of the...
The National Cancer Institute (NCI) awarded a $609,749 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of North Carolina at Chapel Hill (UNC-CH) to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key objectives are to: 1) Create an injectable, biodegradable hydrogel scaffold that can deliver high concentrations of induced neural stem cells (iNSCs) for...
The National Cancer Institute (NCI) awarded a $399,709 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Sieyax LLC, a woman-owned small business located in Broomfield, Colorado. The purpose of this 1-year grant is to develop a novel therapeutic for treating medulloblastoma, the most common malignant brain tumor in children. Specifically, the project aims to optimize the synthesis and evaluate the drug metabolism, pharmacokinetics, and potential toxicity of a lead...
The National Cancer Institute (NCI) awarded a $1,217,906 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Cosmyc Inc. of Dover, DE. The grant, with a funding period from June 18, 2024 to May 31, 2025, will support research into the therapeutic inhibition of the MYC:TRRAP interaction in cancer. This fundamental cancer biology research aims to provide critical insights into the molecular and cellular mechanisms underlying cancer development and progression, with the...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $449,203 to Mayo Clinic Jacksonville to investigate the mechanisms by which proximity to the lateral ventricles and subventricular zone niche in the brain impacts the malignancy of glioblastoma, the most aggressive form of brain cancer. Utilizing novel proteomic and...